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When developing an LC-MS/MS-method matrix effects are a major issue. The effect of
co-eluting compounds arising from the matrix can result in signal enhancement or suppres-
sion. During method development much attention should be paid to diminishing matrix
effects as much as possible. The present work evaluates matrix effects from aqueous
environmental samples in the simultaneous analysis of a group of 9 specific pharmaceuticals
with HPLC-ESI/MS/MS and UPLC-ESI/MS/MS: flubendazole, propiconazole, pipamperone,
cinnarizine, ketoconazole, miconazole, rabeprazole, itraconazole and domperidone. When
HPLC-MS/MS is used, matrix effects are substantial and can not be compensated for with
analogue internal standards. For different surface water samples different matrix effects are
found. For accurate quantification the standard addition approach is necessary. Due to the
better resolution and more narrow peaks in UPLC, analytes will co-elute less with interfer-
ences during ionisation, so matrix effects could be lower, or even eliminated. If matrix effects
are eliminated with this technique, the standard addition method for quantification can be
omitted and the overall method will be simplified. Results show that matrix effects are almost
eliminated if internal standards (structural analogues) are used. Instead of the time-consuming
and labour-intensive standard addition method, with UPLC the internal standardization can
be used for quantification and the overall method is substantially simplified. (J Am Soc Mass
Spectrom 2008, 19, 713–718) © 2008 American Society for Mass SpectrometryEvaluating matrix effects is of the utmost impor-tance when developing a quantitative liquidchromatography/tandem mass spectrometry
(LC-MS/MS) method. Coeluting compounds originat-
ing from the matrix can cause signal enhancement or
suppression. When matrix compounds and analytes
enter the ion source at the same time, the ionization
efficiency of the analyte might be influenced [1]. In this
way, matrix effect can affect the reproducibility and
accuracy of the method. Environmental matrices are
complex and variable. Matrix effects can arise from
unknown and unpredictable compounds. Different au-
thors have studied this phenomenon in environmental
applications [2–6]. Special attention has to be made to
optimize chromatography and sample preparation. The
best option to tackle matrix effects is the use of isotopi-
cally labeled internal standards [1, 2, 5, 7]. Lacking
those, structural analogues are the second best option.
In case of environmental applications, difficulties arise
to find structural analogues, such as other drugs of the
same class, which are certainly not present in the
aquatic environment. Also, the variability of the matrix
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doi:10.1016/j.jasms.2008.01.013should be taken into account when examining and
diminishing matrix effects; different kinds of matrices
should be tested (e.g., different kinds of river water,
waste water treatment plant influent and effluent) [1, 5].
In a previously published article, we examined ma-
trix effects in a high performance liquid chromatogra-
phy (HPLC)-MS/MS analysis of these compounds for
different kinds of surface water [6]. Matrix effects were
very high and different strategies were tried to diminish
these (more extensive sample preparation, lowering the
flow-rate and the use of analogue internal standards).
Matrix effects were not fully eliminated and were
different for different surface water samples. Labeled
internal standards, which compensate for (but do not
eliminate) matrix effects, were not available for these
analytes. The only accurate method for quantification in
this manner is standard addition. The drawback is that
this method is labor-intensive and time-consuming.
Ultraperformance LC (UPLC) is a new LC-system
that is manufactured for the use of columns with sub-2
m particles. These particles should provide more
resolution and more speed [8–10]. Due to better reso-
lution and more narrow peaks, analytes will coelute less
with interferences during ionization, so matrix effects
could be lower, or even eliminated.The objective of the present work is to evaluate and
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715J Am Soc Mass Spectrom 2008, 19, 713–718 COMPARISON OF MATRIX EFFECTS IN HPLC-MS AND UPLC-MScompare matrix effects in the UPLC-MS/MS analysis
with the HPLC-MS/MS analysis of nine pharmaceuti-
cals in aqueous environmental samples. If matrix effects
are eliminated with this technique, the standard addi-
tion method for quantification could be omitted and the
overall method could be simplified.
The pharmaceuticals focused on are produced or
formulated by one pharmaceutical company. These
pharmaceuticals are put on the market in rather high
quantities. The predicted environmental concentrations
(PEC) of these active pharmaceutical ingredients, calcu-
lated based on market volumes and assuming no deg-
radation or absorption (worst-case scenario), are in the
range of 0.03 to 0.23 g/L. According to the EMEA
Guideline CHMP/SWP/4447/00, these PECs are above
the threshold limit of 0.01 g/L for investigation of
potential environmental damage [11].
Experimental
Chemicals and Solutions
Flubendazole, pipamperone, cinnarizine, ketoconazole,
miconazole, rabeprazole, itraconazole, domperidone,
propiconazole (purity all  99%), and two internal
standards [a domperidone analogue (purity 98%) and
an itraconazole analogue (purity  96%)] were pro-
vided by the pharmaceutical company that produces
these analytes (structures included in Supplementary
Figure a1, which can be found in the electronic version
of this article). The other internal standards, hexacon-
azole (purity  99%) was purchased from Sigma-
Aldrich (Bornem, Belgium) and cambendazole (purity
 99%) was purchased from Dr. Ehrenstorfer (Augs-
burg, Germany). Water (H2O), methanol (MeOH), and
acetonitrile (ACN) used during solid-phase extraction
were purchased from Merck (Darmstadt, Germany)
(HPLC-grade). Chloroform (of technical grade) was
from Merck. Water and acetonitrile used for chroma-
tography were of LC-MS-grade and were purchased
from Biosolve (Valkenswaard, The Netherlands). Acetic
acid and ammonium acetate were from Sigma-Aldrich.
Ammonia solution 25% and acetic acid 100% were
purchased from Merck.
Stock solutions were prepared in methanol at a
concentration of 1 mg/mL and stored at 20 °C. From
these stock solutions working solutions were prepared
by diluting with methanol. Working solutions were also
stored at 20 °C.
HPLC
Chromatography. An HP 1100 Agilent system (Agilent,
Avondale, PA) consisting of a membrane degasser, a
Figure 1. Extracted ion chromatogram in HPL
min), (b, above) pipamperone (tr  6.50 min), (c
chromatogram in UPLC analysis at LOD: (a
pipamperone (tr  3.72 min), (c, under) propiconazoquaternary gradient pump, an autosampler (10 °C), and
a column oven (25 °C) was used for separation. All
compounds were separated in one single gradient run.
The separation was performed on a 100 4.6 mm i.d.
pentafluorophenyl column (PFP-column) with 5 m
particles and a Metaguard precolumn (both Varian,
Sint-Katelijne-Waver, Belgium). Eluents were H2O/
ACN [95:5, by vol (A) and 5:95, by vol (B)], both
containing 2 mM ammonium acetate and 2 mM acetic
acid. The flow rate was 1 mL/min. A postcolumn split
was installed (1:5, 200 L flow to the source). Sample
volumes of 20 L were injected. Gradient conditions
were as follows: 0–1.00 min, isocratic 20% B; 1.00–11.50
min, linear from 20% to 100% B; 11.50–16.50 min,
isocratic 100% B; 16.50–17.00 min, linear 100% to 20% B;
17.00–24.00 min, isocratic 20% B.
Mass spectrometry. Analytes were detected by multiple
reaction monitoring (MRM) using electrospray ioniza-
tion mass spectrometry (ESI-MS) on an API-4000 (Ap-
plied Biosystems/MDS SCIEX, Ontario, Canada), with
Turbo Ionspray. During the run the system was in
positive ESI-mode.
The source temperature was 550 °C. The curtain gas
was 15 psig; the nebulizer and drying gas pressures
were both 90 psig. Nitrogen was used both as nebuliz-
ing and drying gas. The capillary voltage was 5000 V.
For each compound, two MRM-transitions were moni-
tored. MRM-transitions and compound-dependent pa-
rameters are summarized in Supplementary Table 1.
The MRM-transitions are measured in periods to obtain
higher signals. In period 1 (0–7.7 min), flubendazole,
pipamperone, rabeprazole, and domperidone are mea-
sured with a dwell time of 100 msec. In period 2 (7.7–9.3
min), propiconazole and ketoconazole are measured
with a dwell time of 200 msec. In period 3 (9.3–10.3
min), itraconazole is measured with a dwell time of 400
ms. In the last period (10.3–24.0 min), cinnarizine and
miconazole are measured with a dwell time of 200 ms.
UPLC
Chromatography. The Acquity Ultra Performance LC-
system (Waters, Milford, MA) consisting of a degasser,
a binary gradient pump, an autosampler (10 °C) and a
column oven (60 °C) were used for separation. All
compounds were separated in one single gradient run.
A 100  2.1 mm i.d. Acquity UPLC HSS T3 column
with 1.8 m particles (Waters) was used for separation
of the compounds. A prefilter was installed before the
column. Eluents were H2O/ACN [95:5, by vol (A) and
5:95, by vol (B)], both containing 2 mM ammonium
acetate and 2 mM acetic acid. The flow-rate was 0.5
alysis at LOD: (a, above) rabeprazole (tr  5.61
ve) propiconazole(tr  9.25 min). Extracted ion
er) rabeprazole (tr  3.35 min), (b, under)C an
, abo
, undle (tr  4.60 min).
alogu
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dient conditions were as follows: 0–4.38 min, linear
from 20% to 100% B; 4.38–6.46 min, isocratic 100% B;
6.46–6.67 min, linear from 100% to 20% B; 6.67–9.59
min, isocratic 20% B.
Mass spectrometry. Analytes were detected by MRM
using electrospray ionization mass spectrometry (ESI-
MS) on an API-4000 (Applied Biosystems/MDS SCIEX),
with Turbo Ionspray. During the run the system was in
positive ESI-mode.
The source temperature was 550 °C. The curtain gas
was 15 psig; the nebulizer gas pressure was 90 psig, and
drying gas pressure was 60 psig. Nitrogen was used
both as nebulizing and drying gas. The capillary voltage
was 2500 V. For each compound 2 MRM-transitions
were monitored. MRM-transitions and compound-de-
pendent parameters are summarized in Supplementary
Table 1. The MRM-transitions are measured in two
periods to obtain higher signals. In period 1 (0–4 min),
flubendazole, pipamperone, rabeprazole, and domperi-
done are measured with a dwell time of 20 ms; in period
2 (4–9.59 min), ketoconazole, itraconazole, cinnarizine,
miconazole, and propiconazole are measured with a
dwell time of 20 ms.
Sample Preparation
Surface water samples were collected and filtered onto
a Metrigard glass fibre filter (0.5 m) in a SolVac holder
Table 1. Matrix effects based on areas and area ratios for the an
UPLC























Internal standards used: (1) itraconazole analogue; (2) domperidone an(both from Pall, Ann Arbor, MI). Filters were washedwith methanol (5 mL per L of the sample). The water
samples were stored at 4 °C until extraction. Before
extraction, the pH of the water samples was adjusted to
7 using a 5% ammonia-solution or a 2% acetic acid-
solution.
Solid-phase extractions were performed on Speedisk
phenyl cartridges (100 mg; 3 mL) of J. T. Baker (Achrom
NV, Machelen, Belgium). The cartridges were condi-
tioned with 3 mL of MeOH and 3 mL of H2O using 60
kPa. Then, the 100 mL surface water sample was
applied using30 kPa. The wash step consisted of 3 mL
of H2O/MeOH (60:40, by vol) (30 kPa). Elution oc-
curred with 2 0.5 mL of MeOH. The NH2-column was
conditioned with 5 mL of CHCl3/MeOH (80:20, by vol)
using 60 kPa. The extract eluted from the phenyl
column was diluted with 4 mL of CHCl3, applied onto
the NH2-column and directly collected. The extract was
evaporated to dryness under a gentle nitrogen stream at
40 °C and redissolved in 100 L (HPLC-extract) or 50
L (UPLC-extract) of H2O/ACN (80/20, by vol); 20 L
(HPLC) or 4 L (UPLC) was injected.
Matrix Effects
Experiments to evaluate matrix effects were in corre-
spondence to the strategy applied by Matuszewski et al.
[12]. MS/MS areas of known amounts of standards (A)
were compared with those measured in a blank water
extract spiked, after extraction, with the same analyte
amount (B). The ratio (B/A  100) is defined as the
s in three different water samples (A, B, and C) with HPLC and
s ME (%) with internal standards
HPLC
C A B C
96.6 130.0 132.7 137.5
51.4 85.4 78.4 73.8
53.5 63.5 67.3 76.1
69.1 122.4 113.1 97.1
83.7 95.2 99.0 92.4
62.6 58.7 59.1 69.0
57.2 148.7 140.8 122.6
22.4 26.5 55.8 55.7
30.9 49.2 77.4 66.8
UPLC
C A B C
98.2 115.4 112.4 97.4
101.7 102.3 112.8 101.1
102.4 103.5 109.2 101.9
88.2 101.7 85.1 87.6
104.6 101.1 97.4 103.0
146.5 112.1 90.0 126.4
74.8 110.1 128.5 120.8
16.5 97.8 94.7 99.3
53.7 110.5 129.9 105.2
e; (3) hexaconazole; (4) cambendazole.alyte
dardabsolute matrix effect (ME%). A value of 100% indicates
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enhancement if the value is 100% and signal suppres-
sion if the value is 100%. Tests were conducted in
triplicate on blank surface water samples, originating
from a local brook, and spiked to obtain a concentration
of 20 ng/L of each pharmaceutical for the HPLC
analysis, and 400 ng/L of each pharmaceutical for the
UPLC analysis. Water samples were first examined for
the presence of possible contaminants.
Results and Discussion
Optimization of UPLC-MS/MS
When changing from HPLC- to UPLC analysis, MS
parameters need to be altered to obtain the highest MS
signals possible. The flow to the source was changed
from 0.2 to 0.5 mL/min, so source parameters needed to
be adjusted. Dwell times were diminished to obtain
enough data points.
In Figure 1, the extracted ion chromatograms of the
HPLC- and UPLC analysis at the limit of detection of
rabeprazole, pipamperone, and propiconazole are
shown. The extracted ion chromatograms of all the
analytes are shown in Supplementary Figure a3. Total
run time is diminished from 24 min to 9.59 min.
Resolution is improved in the UPLC-chromatogram
and peaks are more narrow compared with the HPLC
chromatogram. Analysis speed is improved, and solvent
consumption is diminished.
Matrix Effects
Matrix effects were calculated on three different surface
water samples, taken from three different brooks. The
samples for HPLC analysis were spiked with a standard
mix to obtain a concentration of 20 ng/L; the samples
for UPLC analysis were spiked with a standard mix to
obtain a concentration of 400 ng/L. Itraconazole cannot
be detected with a similar sensitivity in the UPLC
analysis so the concentration was elevated above the
limit of quantification of itraconazole. In Table 1, matrix
effects without internal standards for the HPLC analy-
sis and for the UPLC analysis are shown (for absolute
areas obtained by HPLC and UPLC, see Supplementary
Table 2). The results demonstrate that matrix effect is
substantially reduced when the UPLC analysis is
performed. Matrix interferences coelute less with the
analytes than in HPLC analysis, and signal suppres-
sion is diminished drastically (see also Supplemen-
tary Figure 2).
Also in Table 1, matrix effects with internal stan-
dards are shown (for absolute area ratio, see Supple-
mentary Table 2). Normally, the internal standard with
the highest structural similarity to the analyte is chosen.
This is in most cases also the one that elutes the closest.
If not, the two internal standards (in the same period)
are compared with what extent they compensate best
for the matrix effects. Matrix effects are only minor oreven totally eliminated in UPLC analysis compared
with HPLC analysis. As a result, the labor-intensive and
time-consuming standard addition method can be omit-
ted. Internal standardization can be used, so the overall
method is simplified.
In the UPLC analysis, cambendazole is used as internal
standard for domperidone instead of the domperidone
analogue, because cambendazole elutes more closely to
domperidone than the domperidone analogue.
LOD and LOQ
Limits of detection and quantification (S/N  3 and
S/N  10, respectively) in surface water are shown in
Table 2. Only for itraconazole and cinnarizine, the limits
of detection and/or quantification are higher in the
UPLC analysis than in the HPLC analysis. Part of an
explanation for this might be that dwell time is dimin-
ished drastically in UPLC analysis, so data points are
diminished and sensitivity is negatively influenced.
Conclusions
Matrix effects were examined in surface water anal-
ysis for nine basic pharmaceuticals, using HPLC-
MS/MS and UPLC-MS/MS. In the HPLC-MS/MS
analysis, matrix effects are severe, even with ana-
logue internal standards, and for accurate quantifica-
tion the standard addition method is necessary.
When using UPLC-MS/MS, with the aid of analogue
internal standards, matrix effects are minor or elimi-
nated. In this way, the standard addition method for
quantification can be omitted. Thanks to UPLC, in-
ternal standardization can be used and the overall
method is simplified.
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